

Lamivudine

BRNAD NAME	Epivir [®]
FORM	Oral Solution 50mg/5ml
INDICATION	Prophylaxis against vertical transmission of HIV to neonate, as a constituent of combination therapy. (See WoS guideline for further information)

DOSE RANGE (Commence within 4 hours after birth)

AGE	DOSE	FREQUENCY	ROUTE
Neonate	2mg/kg*	Every 12 hours for four weeks	Oral

*Round calculated dose up to next 0.5mg for ease of administration

CAUTIONS, CONTRA-INDICATIONS AND SIDE EFFECTS

- See Summary of Product Characteristics and most recent edition of BNF for Children (links below)
 - Reduce dose in moderate to severe renal failure

FURTHER INFORMATION

- If the baby is vomiting there should be early recourse to intravenous zidovudine therapy.
- Concomitant administration with co-trimoxazole / Trimethoprim can increase lamivudine exposure. Dose reduction is generally not required (unless renal impairment also present) but infants should be monitored closely

LICENSED STATUS Not licensed in children under 3 months

LINKS [BNF for Children:](#) / [Electronic Medicines Compendium](#)

APPLICABLE POLICIES [West of Scotland Neonatal Guidelines:](#)

Consult local policy if applicable

Document Number:	002	Supersedes:	001
Prepared by:	WoS Neo pharm group	Checked by	June Grant
Date prepared	Aug 2016	Date updated	Apr 2019
Updated by	Maria Tracey	Review Date	April 2022

Dose may vary depending on indication, age, renal function, hepatic function, and concomitant medications. This monograph should be used in conjunction with the package insert, BNF for Children, and Summary of Product Characteristics. For further advice contact your clinical pharmacist or pharmacy department.